Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer

Abstract

Patients and MethodsWe recruited 1,058 participants who received CRC care in a clinic-based setting without preselection for age at diagnosis, personal/family history, or MSI/MMR results. All participants underwent germline testing for mutations in 25 genes associated with inherited cancer risk. Each gene was categorized as high penetrance or moderate penetrance on the basis of published estimates of the lifetime cancer risks conferred by pathogenic germline mutations in that gene. ResultsOne hundred five (9.9%; 95% CI, 8.2% to 11.9%) of 1,058 participants carried one or more pathogenic mutations, including 33 (3.1%) with Lynch syndrome (LS). Twenty-eight (96.6%) of 29 available LS CRCs demonstrated abnormal MSI/MMR results. Seventy-four (7.0%) of 1,058 participants carried non-LS gene mutations, including 23 (2.2%) with mutations in high-penetrance genes (five APC, three biallelic MUTYH, 11 BRCA1/2, two PALB2, one CDKN2A, and one TP53), 15 of whom lacked clinical histories suggestive of their underlying mutation. Thirty-eight (3.6%) participants had moderate-penetrance CRC risk gene mutations (19 monoallelic MUTYH, 17 APC*I1307K, two CHEK2). Neither proband age at CRC diagnosis, family history of CRC, nor personal history of other cancers significantly predicted the presence of pathogenic mutations in non-LS genes. ConclusionGermline cancer susceptibility gene mutations are carried by 9.9% of patients with CRC. MSI/MMR testing reliably identifies LS probands, although 7.0% of patients with CRC carry non-LS mutations, including 1.0% with BRCA1/2 mutations.

Future cancer research priorities in the USA: a Lancet Oncology Commission

“…Multigene testing is broadening the spectrum of cancer risk linked to various hereditary syndromes, frequently identifying individuals with high-penetrance germline mutations that are unexpected from clinical history (eg, colorectal cancer in patients with BRCA1 or BRCA2 mutations). 41,53 …”

Psychological impact of multigene cancer panel testing in patients with a clinical suspicion of hereditary cancer across Spain

“…One of them is the addition of moderate penetrance cancer genes with yet less robust cancer risk estimates and less evidence of their clinical utility . In addition, the number of VUS identified per patient is increased as more genes are analysed, and the possibility of secondary findings arises (findings that are actively sought but unrelated to the indication for ordering the test) . The complexity associated with multigene cancer panel testing challenges genetic counsellors as they try to provide patients with enough information to enable informed decision‐making while avoiding information overload.…”

Opportunistic testing of BRCA1, BRCA2 and mismatch repair genes improves the yield of phenotype driven hereditary cancer gene panels

“…For ovarian cancer (OC), genes were selected according to their association from large case–control studies . Genes for colorectal and adenomatous polyposis panels were included according to prior association with increased risk of colorectal cancer or polyposis and amenable to clinical surveillance …”